Title: Immunobiologicals
Authors: Karthik R, Mohan N, Ravikumar PT
DOI: https://dx.doi.org/10.18535/jmscr/v5i2.140
Abstract
Immunobiologicals are the biologically active agents with immunological actions that are useful for the management of immunologically mediated diseases of infectious or non-infectious origin.
Keywords: Immunobiologicals, Epitope, Interferon, Monoclonal antibodies.
References
1. Taketo Yamada, Keio J Med 2011; 60 (2): 37–46.
2. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-129
3. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, et al. (2001) Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 75: 12198–12208.
4. E. Paszko and M.O. Senge. Immunol-iposomes, Current Medicinal Chemistry, 2012, 19, 5239-5277
5. 5.Robert JK: Immunotoxins for Targeted Cancer Therapy. The AAPS Journal 2006: 8; 532-551.
6. 6.Hutchinson VA, Angenend JL, Mok WL, Cummins JM, Richards AB, Chronic recurrent aphthous stomatitis: oral treatm-ent with low-dose interferon alpha. Mol Biother. 1990 Sep;2(3):160-4.
7. Cornell RC,Greenway HT,Tucker SB, Edwards L,Ashworth S,Vance JC, Tanner DJ, Jaylor EL,Sniles KA,Pert E, Intralesional interferon therapy for Basal cell carcinoma,J Am Acad Dermatol, 1990,oct;23(4 pt1):694-700
8. Ikic D,Padovan I,Pipic N,Knezevic M, Djakovic N,Rode B,Kosutic I,Treatment of squamous cell carcinoma with interferon, Int J Dermatol 1991,Jan 30(1):58-61.
9. Correa AF, Theisen K, Ferroni M, Maranchie JK, Hrebinko R, Davies BJ, Gingrich JR. ,The Role of Interferon in the Management of BCG Refractory Nonmu-scle Invasive Bladder Cancer.Adv Urol. 2015;2015:656918. doi: 10.1155/2015/656918.
10. Spaccarelli N, Rook AH, The use of Interferons in the treatment of Cutaneous T cell Lymphoma, Dermatol Clin. 2015 Oct;33(4):731-45. doi: 10.1016/j.det.2015.05.008. Review.
11. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE, Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up,J Clin Oncol. 1993 Jul;11(7):1368-75.
12. Pogue SL, Taura T, Bi M, Yun Y, Sho A, Mikesell G, Behrens C, Sokolovsky M, Hallak H, Rosenstock M, Sanchez E, Chen H, Berenson J, Doyle A, Nock S, Wilson DS, Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity, PLoS One. 2016 Sep 9;11(9):e0162472. doi: 10.1371/journal.pone.0162472. eCollection 2016.
13. Lengfelder E Berger U, Hehlmann R, Interferon alpha in the treatment of polycythemia vera. Ann Hematol. 2000 Mar;79(3):103-9.
14. Zhang, Ling, Jia Wei Zheng, and Wei En Yuan. “Treatment of Alarming Head and Neck Infantile Hemangiomas with Interferon-α2a: A Clinical Study in Eleven Consecutive Patients.” Drug Design, Development and Therapy 9 (2015): 723–727. PMC.Web. 4 Feb. 2017.
15. van Zonneveld M1, Honkoop P, Hansen BE, Niesters HG, DarwishMurad S, de Man RA, Schalm SW, Janssen HL, Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.Hepatology. 2004 Mar;39(3):804-10.
16. Heise, Ruth et al. “Interferon Alpha Sign-alling and Its Relevance for the Upregu-latory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.” Ed. Andrzej T Slominski. PLoS ONE 11.1 (2016): e0146325. PMC.Web. 4 Feb. 2017.
17. Hammer SM, Kaplan JC, Lowe BR, Hirsch MS. Alpha interferon and acyclovir treatment of herpes simplex virus in lymphoid cell cultures. Antimicrobial Agents and Chemotherapy. 1982;21(4): 634-640.
18. Thomas C. Merigan, M.D., Kenneth H. Rand, M.D., Richard B. Pollard, M.D., Paul S. Abdallah, M.D., George W. Jordan, M.D., and Richard P. Fried, M.D. Human Leukocyte Interferon for the Treatment of Herpes Zoster in Patients with Cancer,N Engl J Med 1978; 298:981-987May 4, 1978DOI: 10.1056/NEJM197805042981801
19. Christopher J. Arpey, Nicole M. Annest, Stephen B. Tucker, Ronald P. Rapini, and Deborah F. MacFarlane,Intralesional and Perilesional treatment of skin cancers, D.F. MacFarlane (ed.), Skin Cancer Manage-ment, DOI 10.1007/978-0-387-88495-0_5,Springer ScienceþBusiness Media, LLC 2010
20. Intralesional interferon α2b treatment of Keratoacanthomas, Chang-Keun Oh et al, Journal of the American Academy of Dermatology, Vol 51, Issue 5, S177 - S180
21. 21.Volberding PA, Mitsuyasu RT, Gola-ndo JP, Spiegel RJ, Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A), Cancer. 1987 Feb 1;59(3 Suppl):620-5.
22. Boot JM, Blog FB, Stolz E. Intralesional interferon alfa-2b treatment of condylo-mata acuminata previously resistant to podophyllum resin application. Genitour-inary Medicine. 1989;65(1):50-53.
23. Kotter I., Gunaydin I., Zierhut M., Stubiger N. (2004a) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33: 320–335.
24. Guttman-Yassky, Emma, Nikhil Dhingra, and Donald Y.M. Leung. “New Era of Biological Therapeutics in Atopic Dermatitis.”Expert opinion on biological therapy 13.4 (2013): 10.1517/14712598.2013.758708. PMC.Web. 4 Feb. 2017
25. Larrabee WF Jr, East CA, Jaffe HS,Stephenson C,Peterson KE,Intralesional Interferon gamma treatment for Keloids and Hypertrophic scars,Arch otolaryngol Head and Neck surg.1990,oct;116(10):1159-62.
26. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y, Evid-ence for the use of intravenous immune-oglobulins--a review of the literature, Clin Rev Allergy Immunol. 2010 Apr;38(2-3):201-69. doi: 10.1007/s12016-009-8155-9.
